45
Participants
Start Date
June 17, 2019
Primary Completion Date
May 31, 2022
Study Completion Date
May 31, 2022
KN026 10 mg/kg QW
10 mg/kg QW as safety run-in dosage
KN026 20 mg/kg Q2W
20 mg/kg Q2W as target dosage
KN026 30 mg/kg Q3W
30 mg/kg Q3W as another target dosage
307 Hospital of PLA, Beijing
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
INDUSTRY